Genscript Biotech FCF Growth
The Year-over-Year Free Cash Flow Growth of Genscript Biotech (1548.HK) as of Oct 12, 2026 is 2,722.86 %. In the previous year, Year-over-Year Free Cash Flow Growth was 97.93 % — a change of 2,680.49% (higher).
Get this data via API
Financial Data API
FCF Growth
2,722.86 %
YoY
2,680.49%
Last updated:
The Genscript Biotech FCF Growth history
3 Years
10 Years
25 Years
Max
| YEAR | FCF Growth | YoY |
|---|---|---|
| 2,722.86 % | +2,680.49% | |
| 97.93 % | -404.41% | |
| -32.17 % | +30.39% | |
| -24.67 % | -2,246.12% | |
| 1.15 % | -101.22% | |
| -94.53 % | -40.64% | |
| -159.25 % | -105.11% | |
| 3,117.97 % | -2,466.74% | |
| -131.74 % | -244.34% | |
| 91.27 % | -45.16% | |
| 166.44 % | — |
Genscript Biotech Stock analysis
Frequently Asked Questions about Genscript Biotech stock
Year-over-Year Free Cash Flow Growth of Genscript Biotech is 2,722.86 % in 2025.
On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Genscript Biotech since 2006 – with annual values, charts, and detailed analysis.
FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.
To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.
Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Genscript Biotech historically and in real time.
Growth — Genscript Biotech
All Key Metrics — Genscript Biotech
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth